Direktorat Registrasi ObatValid

DEXAMETHASONE SODIUM PHOSPHATE

BPOM Number: GKL7820907643A1
Approved: 14 July 2026
Expiry: 29 March 2031
Form: INJEKSI

About This Registration

DEXAMETHASONE SODIUM PHOSPHATE is a BPOM-registered direktorat registrasi obat in Indonesia, registered under number GKL7820907643A1. Its current registration status is Valid, with the licence valid until 29 March 2031. The product is registered to INDOFARMA - INDONESIA. BPOM first approved this registration in July 2026. All registration data is sourced directly from the official BPOM public database and updated daily.

Registration data updated by BPOM

This product's registration details were changed on 15 July 2026. This may reflect a status change, renewal, or correction by BPOM.

Registration Details

Application: newaero
Packaging: DUS, 100 AMPUL @ 1 ML
Department: Direktorat Registrasi Obat
Data Last Updated: 15 July 2026

Retail Audit Service

Get detailed market intelligence for this product across Indonesian retail channels

Multiple cities available

Custom questionnaires

Professional shoppers

Detailed reporting

Starting from $50 per city

What's included in the audit service?

Stock availability and positioning verification

Price checking and competitor analysis

Display quality and promotional material assessment

Store condition and customer experience evaluation

Custom questions tailored to your research needs

Professional photographs and detailed reports

Registered Owners

INDOFARMA - INDONESIA
KAB. BEKASI
NPWP: 12345678910
owner
View profile →

Manufacturing Sites

INDOFARMA - INDONESIA
KAB. BEKASI
primary
View profile →

Ingredients (1)

DEXAMETHASONE SODIUM PHOSPHATE

Market Intelligence

Owner Portfolio: INDOFARMA - INDONESIA holds 195 BPOM registrations
Manufacturer Scale: INDOFARMA - INDONESIA produces 195 registered products
Registration Age: Registered for 1 month
Update Status: Recently updated (49 days ago)

FDA Cross-Reference

via openFDA

Generic Name: DEXAMETHASONE
Product Type: HUMAN PRESCRIPTION DRUG
Route of Administration: ORAL

Data sourced from the U.S. FDA drug label database (openFDA). May not exactly match this product variant.

Is this your product?